François Binette, PHD

François Binette, joined Renovaro Biosciences as Executive Vice President for Research and Development, bringing over 25 years of product development expertise in Advanced Therapies and Regenerative Medicine.

Dr. Binette’s broad industry experience spans a wide range of serious medical conditions, from orthopedics to ophthalmology, CNS, and immuno-oncology, driving cutting edge innovation from bench top to bedside. During his first industry appointment at Genzyme Tissue Repair in Cambridge, he helped pioneer Carticel™ for cartilage repair, the first FDA BLA-approved cell therapy product for human use.

He then led R&D for Biosyntech, a startup biomaterials company in Montreal applying its proprietary platform for various tissue engineering and drug delivery applications. Dr. Binette then joined the DePuy Franchise of Johnson and Johnson (JNJ), the second largest orthopedic business worldwide where he led several innovative regenerative medicine combination product development initiatives from discovery to approved clinical trials in US and Europe.

Following JNJ, Dr. Binette joined the Spinal and Biologics business unit of Medtronic, the world’s largest medical device company, developing biologics, active devices, and combination products for interventional spine procedures for back pain.

More recently as part of the Lineage Cell Therapeutics executive leadership team, Dr. Binette led the CNS franchise as well as general pipeline development, contributing to one of the largest non-cancer cell therapy corporate partnership deals with Genentech worth over $650 million in upfront and milestone payments. He received his PhD from Laval University in Québec City, followed with post-doctoral training at the Sanford-Burnham institute in La Jolla, and Harvard Medical School in Boston.

BACK